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Recent whole-genome sequencing studies have identified millions of somatic variants
present in tumor samples. Most of these variants reside in non-coding regions of the
genome potentially affecting transcriptional and post-transcriptional gene regulation.
Although a few hallmark examples of driver mutations in non-coding regions have
been reported, the functional role of the vast majority of somatic non-coding variants
remains to be determined. This is because the few driver variants in each sample
must be distinguished from the thousands of passenger variants and because the
logic of regulatory element function has not yet been fully elucidated. Thus, variants
prioritized based on mutational burden and location within regulatory elements need
to be validated experimentally. This is generally achieved by combining assays that
measure physical binding, such as chromatin immunoprecipitation, with those that
determine regulatory activity, such as luciferase reporter assays. Here, we present an
overview of in silico approaches used to prioritize somatic non-coding variants and the
experimental methods used for functional validation and characterization.
Keywords: cancer, non-coding mutation, driver mutation, hotspot analysis, motif analysis
INTRODUCTION
Cancer initiation, progression, maintenance, and metastasis originate from somatic single
nucleotide variants (SNVs), small insertions and deletions, structural variants, and epigenetic
alterations (Helleday et al., 2014). In particular, recent whole-genome sequencing studies of tumor
samples, through collaborative projects such as The Cancer Genome Atlas (TCGA) and the
International Cancer Genome Consortium (ICGC), have identified millions of somatic SNVs
associated with different types of cancers (Cancer Genome Atlas Research Network, 2008, 2013;
Nik-Zainal et al., 2016). Although, these projects and follow-up studies have been successful at
identifying common sets of mutated genes and pathways across many cancer types, the functional
role of most mutations detected remains to be determined. Indeed, the main challenge in analyzing
the genetics underlying cancer is to distinguish driver mutations (i.e., positively selected mutations
that provide growth advantage to tumor cells) from passenger mutations (i.e., inert mutations
that do not confer any growth advantages) (Khurana et al., 2016). This requires the integration
of computational analyses that predict functional SNVs with experimental pipelines to validate
and characterize those SNVs.
Most studies have focused on characterizing the functional impact of SNVs on coding regions
given that it is relatively straightforward to computationally predict how a protein sequence
and/or structure will be affected by a missense, nonsense or frameshift mutation. However, the
vast majority of SNVs identified in cancer samples reside in non-coding regions of the genome
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(Araya et al., 2016). These non-coding SNVs can affect the
binding of transcription factors (TFs), RNA-binding proteins
(RBPs), and micro RNAs (miRNAs) (Figure 1) (Khurana et al.,
2016). This in turn affects multiple gene regulatory functions
including chromatin structure or accessibility, transcription,
DNA methylation, splicing, as well as 5′ and 3′ untranslated
region (UTR) function, which ultimately increases or decreases
the production, stability and translation efficiency of mRNA
transcripts (Khurana et al., 2016).
Despite recent advances in the understanding of the
downstream consequences of non-coding SNVs, it remains
a challenge to identify non-coding driver mutations and the
mechanisms through which they effect biological functions. First,
as stated above, non-coding SNVs can affect multiple regulatory
functions including transcriptional and post-transcriptional
regulation. Second, non-coding regions present higher mutations
rates than coding regions, due to weaker selective pressure
(Weinhold et al., 2014). As a result, parsing through a higher
number of passenger mutations to find non-coding driver SNVs
becomes a difficult statistical and computational task (Vogelstein
et al., 2013). Third, it is challenging to computationally predict
whether a non-coding SNV affects gene expression or mRNA
stability because the logic involved in regulatory element
function has not yet been fully elucidated. Thus, computational
predictions of altered regulatory function need to be confirmed
by extensive experimental validation using reporter assays,
genome editing, measurement of endogenous gene expression,
and/or chromatin immunoprecipitation.
Early studies that identified non-coding driver SNVs
compared the sequence of regulatory regions of candidate
FIGURE 1 | Non-coding cancer mutations affecting transcriptional and
post-transcriptional regulation. Somatic mutations (present in tumor but not in
matched normal tissue samples) can alter gene regulation by affecting the
binding of a transcription factor (TF) to a regulatory region, the binding of RNA
binding proteins (RBPs) or miRNAs to untranslated regions (UTRs) in the
mRNAs, or affect normal splicing. TF, purple; RBP, orange; regulatory region,
blue; UTR, green; coding region, yellow; SNV, red.
cancer-related genes between tumor and non-tumor samples in
order to determine whether these mutations disrupt or create TF
binding sites. For example, SNVs were identified in the GTAAC
sequence within the first intron of MYC in samples from multiple
patients with Burkitt lymphomas (Zajac-Kaye et al., 1988). These
mutations, which lead to increased MYC expression, abrogated
the binding of a then unidentified TF. Since this early work,
targeted studies have identified several mutations in regulatory
regions, both in tumor samples and in patients with increased
cancer incidence (Stenson et al., 2009).
More recently, whole-genome sequencing of matched tumor
and normal samples has enabled the identification of millions
of SNVs. However, the identity of the SNVs responsible for
driving cancer and those that constitute passenger mutations
remains to be determined. Two pioneering studies showed
that mutations present in the telomerase reverse transcriptase
(TERT) promoter in tumor samples of patients with melanoma
lead to increased TERT mRNA expression (Horn et al., 2013;
Huang et al., 2013). These studies identified two independent
C > T transitions, at around −100 bp from the TERT
transcription starting site (TSS), that create a 11 bp nucleotide
stretch containing a consensus binding site for E-twenty-
six (ETS) TFs. Additionally, other mutations in the TERT
promoter have been found in melanoma as well as in
other cancer types such as ovarian, follicular thyroid, and
meningiomas (Horn et al., 2013; Goutagny et al., 2014; Liu
et al., 2014; Wu et al., 2014). More recently, mutations in
the regulatory regions of other cancer-related genes have been
identified, including recurrent mutations in the promoters
of PLEKHS1, WDR74, SDHD, and FOXA1 that alter gene
expression levels, TF binding and that are associated with
poor prognosis (Fredriksson et al., 2014; Weinhold et al.,
2014; Nik-Zainal et al., 2016; Rheinbay et al., 2017). Here,
we present an overview of state-of-the-art approaches to
computationally predict and functionally validate driver somatic
non-coding SNVs, as well as recent findings associated with
cancer.
COMPUTATIONAL APPROACHES TO
IDENTIFY NON-CODING SNVs
Computational approaches to predict functional SNVs within
regulatory regions share a common general pipeline, including
the identification of somatic SNVs, comparison with common
germline variants, constraining the analysis to regulatory regions
(in some cases, close to cancer-related genes), identification of
mutational hotspots, and determining altered TF binding sites
(Figure 2).
The identification of somatic SNVs requires comparing
the genome sequences of tumor samples with matched
normal tissue samples. This is a challenging task because
somatic SNVs occur at low frequency in the genome (0.1–
100 SNVs per megabase), which needs to be distinguished
from errors derived from whole-genome sequencing and
genome alignment pipelines (Lawrence et al., 2013; Alioto
et al., 2015). Thus, most methods used to identify somatic
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FIGURE 2 | Computational pipeline to prioritize somatic SNVs in regulatory
elements. Whole-genome sequencing (WGS) of matched tumor and normal
samples are analyzed to identify somatic mutations. Identification of mutations
within regulatory regions is performed by restricting analyses to promoter
regions, generally defined around transcription start sites, and distal elements
such as enhancers, predicted based on DHSs and/or histone marks. Hotspot
analyses are used to identify regions with increased mutational burden
compared to background models based on mutational frequency in
neighboring regions and/or regions with similar functional roles. Covariates
such as replication timing or gene expression levels can be included to
account for mutational heterogeneity across the genome. Motif analyses are
performed to predict differential TF binding between SNV alleles. Prioritized
non-coding SNVs are usually validated in functional assays.
SNVs require high sequencing depths (usually 30–300x) and
paired-end reads, leading to elevated sequencing costs (Alioto
et al., 2015). In addition, given that tumors are comprised
of heterogeneous populations of cells, many functional
SNVs may be present at a low frequency in patient samples
(Carter et al., 2012; Nik-Zainal et al., 2012b). Therefore, while
high-frequency SNVs can be identified provided that the
sequencing depth is sufficient enough and that computational
pipelines accommodate for sequence heterogeneity, low-
frequency SNVs may require single-cell genome sequencing
approaches (Navin et al., 2011; Zong et al., 2012; Eirew et al.,
2015).
Several computational methods have been developed to
identify somatic SNVs, including: (1) those that separately call
SNVs in tumor and normal samples and then identify tumor-
specific SNVs by comparison, such as GATK (DePristo et al.,
2011), GATKcan (Hsu et al., 2017), and EBCall (Shiraishi et al.,
2013); and (2) those that concurrently analyze tumor-normal
samples using heuristic methods or statistical models, such as
MuTect (Cibulskis et al., 2013), VarScan (Koboldt et al., 2009,
2012), and Strelka (Saunders et al., 2012) (Table 1). While
the first type of methods models sequencing errors based on
statistical parameters from the sequencing reads or from non-
matched normal samples, the second type of methods compare
matched tumor-normal samples to distinguish true mutations
from sequencing errors. Even though these algorithms have
been used as stand-alone methods to call SNVs, some studies
have used a combination of methods for a “wisdom of the
crowd” approach with the goal of increasing the confidence
in the SNVs detected (Weinhold et al., 2014; Melton et al.,
2015).
HOTSPOT ANALYSES BASED ON
MUTATION FREQUENCY
Among the millions of non-coding somatic SNVs identified
in different cancers, only a small number are expected to be
drivers. Given that it is not currently possible to experimentally
test most of the SNVs identified, methods have been developed
to prioritize which SNVs are more likely to be functional.
A common approach to prioritize somatic SNVs is to determine
genomic regions with high mutation frequency across different
cancer samples. Given the billions of bases in the human genome,
the thousands of mutations per cancer sample, and that we only
have sequencing data for a few thousand tumors, the chances of
detecting a significantly enriched mutation across cancers after
multiple hypothesis testing correction is almost null.
Currently, there are two complementary strategies, frequently
used together, to increase the power to detect non-coding driver
mutations. One strategy is to focus on DNA elements that are
expected to have a regulatory function. For example, promoter
regions are relatively easy to determine by selecting regions
up- and downstream of transcription start sites, while distal
elements are usually determined based on DNase hypersensitivity
sites (DHSs) or histone marks such as H3K4me and H4K27ac
(Figure 2) (ENCODE Project Consortium, 2012). Further, some
studies constrain the analyses to the regulatory regions of cancer-
related genes such as those compiled in the Cancer Gene Census
(Futreal et al., 2004). Overall, restricting the analysis to a set of
regulatory regions reduces the search space for SNVs and, thus
increases the power to detect driver mutations.
The second strategy is the identification of clusters of SNVs
within short DNA windows, called hotspots, rather than single
mutations (Figure 2). This reduces dimensionality and increases
the frequency of SNVs within each DNA window leading to
increased statistical power. The identification of these mutational
hotspots across cancers involves comparing the SNV frequency
within a DNA window to a background distribution of SNV
frequencies. These methods can be divided into local and global
models, comparing the SNV frequencies to other windows in
neighboring genomic regions or to functionally similar regions
(e.g., other promoters or enhancers), respectively. The window
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TABLE 1 | List of computational methods and databases to identify somatic
SNVs, incorporate background models to predict functional non-coding SNVs,
predict altered TF binding sites, and integrate with functional annotations.
Goal Method/database Reference
GATK DePristo et al., 2011
GATKcan Hsu et al., 2017
Identification of somatic EBCall Shiraishi et al., 2013
SNVs MuTect Cibulskis et al., 2013
Varscan Koboldt et al., 2009
Varscan2 Koboldt et al., 2012
Strelka Saunders et al., 2012
Incorporation of MutSigNC Rheinbay et al., 2017
background models for LARVA Lochovsky et al., 2015
non-coding SNVs MOAT Lochovsky et al., 2017
FIMO Grant et al., 2011
MotifbreakR Coetzee et al., 2015
BEEML-PBM Hume et al., 2015
TFM-pvalue Touzet and Varre, 2007
Prediction of TF MotifLocator Claeys et al., 2012
binding sites CIS-BP Weirauch et al., 2014
Jaspar Khan et al., 2017
Uniprobe Hume et al., 2015
Transfac Matys et al., 2003
RegulomeDB Boyle et al., 2012
Integration with Funseq2 Fu et al., 2014
functional annotation of
non-coding regions
ENCODE Project ENCODE Project
Consortium, 2012
Roadmap Epigenomics Roadmap Epigenomics
Consortium et al., 2015
FANTOM Consortium Andersson et al., 2014
GTEx Project GTEx Consortium, 2013
This list is not exhaustive, thus, the authors apologize for any method/database not
referenced in this table.
size selection can vary widely between analysis, ranging from
50 bp (Weinhold et al., 2014) up to 500 kb (Fujimoto et al.,
2016). While short windows provide higher resolution, allowing
one to identify functional promoter or enhancer regions, they
lead to low statistical power and thus many functional regions
may be missed (Fujimoto et al., 2016). Long windows do
not have the resolution to detect functional promoters or
enhancers but allow for the identification of covariates, regional
features associated with genomic heterogeneity in mutation
frequency, such as replication timing and gene expression
levels (Fujimoto et al., 2016). Both types of methods can be
integrated with one another to increase the chances of detecting
driver mutations. For example, a recent study analyzing 863
human tumors has identified recurrent mutations in regulatory
elements upstream of TERT, PLEKHS1, WDR74 and SDHD
in different types of cancer by using 50 bp windows to
find hotspots, and regional recurrence approaches that take
into account length and replication timing (Weinhold et al.,
2014).
Although studies using low tumor sample numbers may be
underpowered to identify hotspot regions, large samples sizes
can also be challenging to analyze. This is because large sample
sizes frequently lead to larger lists of potentially significant
genes which in many cases do not have cancer-related functions,
suggestive of a high false positive prediction rate (Lawrence
et al., 2013). This stems from using background mutation
models that do not account for mutational heterogeneity between
samples and across genomic regions (Lawrence et al., 2013).
Pipelines such as MutSigNC have been developed to correct
for variation in mutation frequency by considering patient-
specific mutation rates, patient-specific sequencing coverage,
information about regional mutation clustering, and using as
background the mutation rates of promoters (Rheinbay et al.,
2017) (Table 1). Other computational frameworks have also been
used to also include distal elements in the analyses, including
LARVA that incorporates background models for non-coding
regions by integrating SNVs with a comprehensive set of non-
coding functional elements based on DHSs and histone marks
(Lochovsky et al., 2015) (Table 1). In addition, LARVA uses
regional genomic features like replication timing allowing to
better estimate local mutation rates and mutational hotspots.
Further covariates can be included while modeling mutation
frequencies. For instance, recent studies have shown that some
breast tumors have mutations mediated by the alipoprotein
B messenger RNA-editing enzyme catalytic (APOBEC) which
have been found to occur in dense hypermutated regions in
the genome (kataegis) (Nik-Zainal et al., 2012a; Alexandrov
et al., 2013). These mutations share a sequence pattern (TCW,
where W is A/T), which can be used to assign mutations a
probability of being originated by APOBEC activity (Roberts
et al., 2013), leading to a more conservative approach to call
candidate mutations. This approach identified SNVs in breast
cancer samples within the regulatory regions of FOXA1, RMRP,
and NEAT1 that affect gene expression levels (Rheinbay et al.,
2017). Alternatively, covariates can be avoided altogether by
using a non-parametric, permutation-based approach such as
MOAT, that does not make assumptions about the mutation
process except for requiring that the background-mutation rate
changes smoothly with genomic features (Lochovsky et al.,
2017) (Table 1). The variety of co-existing computational
approaches, background models, and covariates included in those
models, highlights the challenges currently faced in identifying
mutational hotspots associated with cancer.
PREDICTION OF NON-CODING SNVs
WITH HIGH FUNCTIONAL IMPACT
Hotspot analyses allow for the prioritization of candidate cancer
driver SNVs. However, to further narrow down the set of
functional SNVs and predict the functional impact of these
SNVs, location and sequence context of the mutations must be
integrated with functional models of non-coding regions. One of
the most widely used approaches to prioritize SNVs in regulatory
regions involves the identification of TF binding sites created
or disrupted by the mutations (Figure 2). These TF binding
differences between SNV alleles can be predicted based on DNA
specificities determined by protein-binding microarrays, SELEX,
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bacterial one-hybrid assays, or chromatin immunoprecipitation
(ChIP) followed by next generation sequencing (ChIP-seq)
(Noyes et al., 2008; Jolma et al., 2013; Weirauch et al., 2014).
Currently, DNA binding specificities have been determined for
nearly half of human TFs, which are available in different
repositories such CIS-BP, Jaspar, Uniprobe, and Transfac (Matys
et al., 2003; Weirauch et al., 2014; Hume et al., 2015; Khan
et al., 2017) (Table 1). Differences in TF binding between SNV
alleles can be predicted using position weight matrices (PWMs),
probabilistic representations of DNA binding specificities, and
motif prediction algorithms such as FIMO (Grant et al., 2011),
MotifbreakR (Coetzee et al., 2015), BEEML-PBM (Hume et al.,
2015), TFM-pvalue (Touzet and Varre, 2007), and MotifLocator
(Aerts et al., 2005; Claeys et al., 2012) (Table 1). For example,
MotifLocator, a tool to score how mutations affect wild-type TF
binding sites, led to the identification of gain of binding sites
for RB1, E2F1 and ETS to multiple promoter regions in tumor
samples from TCGA (Kalender Atak et al., 2017). Similarly,
mutations in the promoter of FOXA1, a known gene driver in
breast cancer, were found to increase E2F binding using TFM-
pvalue (Rheinbay et al., 2017). Loss of TF binding sites have
also been widely associated with cancer. For example, many
recurrent mutated regions in cancer genomes have been found
to overlap with CTCF binding sites, showing a possible selection
for these mutations (Katainen et al., 2015; Lochovsky et al.,
2015; Piraino and Furney, 2017). In addition, disruption of FOX
TF binding sites in the BCL6 promoter have been reported in
follicular lymphoma using an integrative approach that identifies
functional regulatory mutation blocks (Batmanov et al., 2017).
Interestingly, both the creation and disruption of binding sites
for the same TFs have been linked to cancer. For example,
by integrating motif analyses with evolutionary conservation,
creation of ETS binding sites were determined in the ANKRD53
promoter, while disruption of ETS binding sites were identified
in the TAF11 and SDHD promoters (Weinhold et al., 2014).
In addition, motif analyses can integrate functional
annotations of regulatory sequences (including DHSs, histone
marks, and sequence conservation) and TF expression levels
such as those provided by the ENCODE, Roadmap Epigenomics,
FANTOM, and GTEx Projects to constrain the analyses to TFs
expressed and regulatory elements active in the tissues of interest
(ENCODE Project Consortium, 2012; GTEx Consortium, 2013;
Andersson et al., 2014; Roadmap Epigenomics Consortium
et al., 2015) (Table 1). These approaches include RegulomeDB
(Boyle et al., 2012) that considers functional annotations for
the regulatory regions, and Funseq2 (Fu et al., 2014) that also
considers sequence conservation across species and recurrence
of somatic mutations in cancer (Table 1).
Although motif analyses have been instrumental to predict
altered TF binding, these methods are limited by the availability
of high-quality PWMs and by the high false positive and false
negative predictions rates of motif finding algorithms (Zia and
Moses, 2012; Weirauch et al., 2014; Sewell and Fuxman Bass,
2017). Indeed, motif analyses can rarely distinguish between
different members of a TF family, and often miss the TF that
differentially binds to SNV alleles (Weirauch et al., 2014). Thus,
SNVs in regulatory regions predicted to be functional based on
hotspot and motif analyses, need to be experimentally tested to
determine whether these mutations actually affect TF binding.
EXPERIMENTAL VALIDATION OF
DIFFERENTIAL TF BINDING BETWEEN
SNV ALLELES
Multiple complementary experimental methods can be used to
determine TF binding including ChIP, electrophoretic mobility
shift assays (EMSA), and enhanced yeast one-hybrid (eY1H)
assays (Figure 3). ChIP has been successfully used to study
differential TF binding between non-coding SNV alleles in vivo
(Figure 3A). For example, several studies have identified
mutations in the TERT promoter, such as G228A, that lead
to the creation of de novo bind site for ETS factors (Horn
et al., 2013; Huang et al., 2013). However, the identity of the
specific ETS factor involved remained elusive until a recent study
analyzing ChIP-seq data from the ENCODE Project (ENCODE
Project Consortium, 2012), identified GABPA as the TF that
differentially binds and regulates TERT expression (Bell et al.,
2015). In particular, GABPA was found to be bound to the
TERT promoter in heterozygote cell lines harboring the G228A
mutation, specifically to the mutant allele, while other ETS factors
did not show significant binding. Although ChIP is the method of
choice to validate in vivo differential TF binding between alleles,
this method requires a priori TF candidates as it can only test
one TF at a time. Further, given that ChIP tests for in vivo TF
binding, experiments need to be performed in cell lines harboring
the mutations or using patient samples, which are frequently
challenging to obtain.
A recent study using enhanced yeast one-hybrid (eY1H)
assays, a method that tests protein-DNA interactions in the
milieu of the yeast nucleus, has increased the screening
throughput for TF binding differences between SNV alleles by
testing > 1,000 TFs in parallel, without the need for antibodies
or patient samples (Figure 3C) (Fuxman Bass et al., 2015).
Although this study has focused on germline variants associated
with different genetic diseases, the experimental eY1H pipeline
can also be used to evaluate somatic SNVs in cancer. Given that
ChIP, EMSA and eY1H assays measure physical DNA binding,
rather than regulatory activity, interactions identified by these
methods need to be tested in human cell lines to determine
the SNV impact on gene regulation by using transient reporter
assays, or endogenous gene expression measurements following
TF knockdown/knockout.
EXPERIMENTAL VALIDATION OF
ALTERED GENE EXPRESSION BY SNVs
Driver mutations that affect regulatory regions are expected
to affect the expression of a target gene. Functional
validation assays such as those using luciferase reporters
have been widely used to determine expression differences
between non-coding SNV alleles (Figure 4A) (Huang et al.,
2013; Denisova et al., 2015; Fuxman Bass et al., 2015;
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FIGURE 3 | Overview of assays to measure differential TF binding between non-coding SNV alleles. (A) ChIP against a candidate TF can be performed in cells that
are heterozygous for the SNV. Sequencing of the amplified regions (or allele-specific qPCR) can determine relative TF binding between wild-type (wt) and mutant
(mut) alleles. Alternatively, ChIP-seq data can be analyzed to detect biases in the number of sequencing reads between alleles. The figure shows an example of loss
of TF binding caused by a mutation. (B) EMSA can be performed to determine differential TF binding to oligonucleotides containing wt or mut SNV alleles by using
nuclear extracts (NE) followed by super-shifts using antibodies against the candidate TF (α-TF), or by incubating with extracts overexpressing the TF. (C) eY1H
assays can test the binding of >1,000 TFs to wild-type and mutant allele sequences. In this assay, each DNA sequence is cloned upstream the HIS3 and LacZ
reporters and integrated into the yeast genome. Interactions are tested by mating with yeast strains expressing different TFs in an arrayed format system. Differential
TF interactions (highlighted in red) can be determined by comparing screening results between alleles.
FIGURE 4 | Functional assays to measure altered gene expression and phenotypic parameters induced by SNVs in regulatory regions. (A) Reporter assays can be
used to determine differential expression induced by wild-type and mutant regulatory elements in transiently transfected cells. (B) In MPRAs wild-type and mutant
alleles for hundreds/thousands of non-coding SNVs can be tested in parallel for changes in transcriptional activity. ∼200 bp sequences containing the SNVs are
cloned upstream of an inert ORF and associated with random barcodes. Cells are then transfected with the pooled library, ORF-specific mRNA is isolated, and
barcode tags are counted using next-generation sequencing (NGS). By comparing the number of reads per allele in the mRNA and the plasmid populations, relative
expression levels can be determined. (C) Functional validation and follow-up studies can be performed by determining differences in endogenous gene expression,
proliferation, migration, and viability, among other assays, using cells engineered to carry the mutation.
Rheinbay et al., 2017). In addition, reporter assays can be
used to validate differential TF binding determined based on
physical binding assays, by overexpressing or knocking down TF
expression and measuring the impact on reporter activity driven
by the wild-type or mutant regulatory sequences. Although
useful for functional validation, reporter assays are generally
low-throughput and cannot keep pace with the discovery of new
mutations.
Recent studies using massively parallel reporter assays
(MPRAs), a high-throughput technology based on barcodes and
next generation sequencing, have made progress in determining
whether germline SNVs associated with genetic disorders affect
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transcriptional regulation (Figure 4B) (Melnikov et al., 2012;
Mogno et al., 2013; Tewhey et al., 2016; Ulirsch et al., 2016). In
particular, differential transcriptional activity has been detected
for hundreds of expression quantitative trait loci (eQTL) and
disease-associated variants. While this method remains to be
applied to cancer SNVs, it is expected that MPRAs will constitute
an essential tool for identifying functional non-coding somatic
SNVs. Although powerful, MPRAs are not free of caveats. For
instance, current oligonucleotide synthesis pipelines only allow
for a maximum DNA fragment length of∼230 nucleotides. Thus,
non-coding mutations are not usually tested within full length
regulatory elements (that can be up to several kilobases), which
may be hamper the ability of MPRAs to detect changes in gene
expression. This limitation may be overcomed as pooled and
arrayed oligonucleotide synthesis technologies are adapted to
generate longer DNA sequences. Another limitation of MPRAs
is that reporter activity is generally tested using episomal
constructs, or randomly integrated lentiviral constructs, that do
not reflect the endogenous genomic context where the non-
coding mutations reside (Tewhey et al., 2016; Ulirsch et al.,
2016). Thus, the functional effect of many SNVs on target
gene expression may be over or underestimated. Downstream
validation studies in the appropriate genomic context can be
conducted by introducing the SNV in the endogenous locus
using genome editing technologies such as the CRISPR/Cas9
system, zinc finger nucleases, or transcription activator-like
effector nucleases (Figure 4C) (Claussnitzer et al., 2015; Elkon
and Agami, 2017). These studies, ultimately need to be followed-
up using assays that demonstrate the biological significance of the
SNVs in cancer by measuring different oncogenic properties such
as invasion, proliferation, and viability (Figure 4C).
SNVs AFFECTING DISTAL REGULATORY
ELEMENTS
Compared to promoters, dissecting the functional effects of
mutations in distal regulatory elements such as enhancers is a
more complex task as it is not trivial to determine which of
these elements are functional in different cells/conditions nor
the identity of the target gene involved. This, and the fact that
including distal elements in hotspot analyses increases the search
space and reduces statistical power are the main reasons why
most studies characterizing germline and somatic non-coding
SNVs have focused on promoter regions (Stenson et al., 2009;
Rheinbay et al., 2017).
Several technologies have been used to identify promoter-
enhancer pairs interacting through chromatin loops. These
methods, that involve crosslinking and ligation of spatially
closed genomic regions, such as Hi-C (Lieberman-Aiden et al.,
2009) and chromatin conformation capture by paired-end tag
sequencing (ChIA-Pet) (Li et al., 2012), have been used to
capture the potential regulatory effect of enhancer mutations.
For example, a recent study found that a somatic SNV (C > T)
four kilobases upstream of the transcriptional start site of the
LMO1 oncogene generated a de novo binding site for the MYB
TF in patients with T-cell acute lymphoblastic leukemia (Li Z.
et al., 2017). A combination of ChIP-Seq of MYB, followed
by ChIA-PET and luciferase assays revealed that this mutation
induced the formation of an aberrant transcriptional enhancer
complex leading to increased expression of the LMO1 oncogene.
Thus, integration of chromatin interaction data can identify the
gene targets of distal regulatory elements and determine how
mutations in those elements affect looping interactions leading
to changes in gene expression.
NON-CODING SNVs AFFECTING
POST-TRANSCRIPTIONAL REGULATION
Non-coding mutations not only affect transcriptional regulation
but can also affect other biological processes such as mRNA
stability, translation efficiency, or splicing. Mutations in UTRs
can affect mRNA stability and translation efficiency by altering
interactions with RNA-binding proteins and miRNAs (Figure 1)
(Khurana et al., 2016). For example, mutations in the 5′
UTR of RB1 alter UTR conformation and mRNA stability in
retinoblastoma (Kutchko et al., 2015), while mutations in the
5′ UTR of BRAC1 in breast cancer patients reduce translation
efficiency (Signori et al., 2001; Wang et al., 2007). In addition,
mutations in the 3′ UTR of BRCA1 were found to introduce a
functional miRNA-103 target site in a breast cancer case leading
to reduced BRAC1 levels (Brewster et al., 2012). As with SNVs
in transcriptional regulatory regions, the functional impact of
UTR mutations need to be tested in experimental assays. Low-
throughput reporter assays have been used to quantify differences
in mRNA levels by cloning the relevant UTR regions upstream
or downstream of the coding region of GFP or luciferase. More
recently, massively parallel functional annotation of sequences
from 3′ UTRs (fast-UTR) has been developed, which was used to
discover 87 novel cis-regulatory elements and measure the effects
of known gene variations in 3′ UTRs (Zhao et al., 2014).
Mutations in the exon–intron boundaries, introns, and coding
regions can affect splicing and lead to the upregulation oncogenic
isoforms or the downregulation of tumor suppressor isoforms.
Various cancer tumor suppressor genes such as TP53, ARID1A,
PTEN, CHD1, MLL2, and PTCH1 were found to carry mutations
in the exon–intron boundaries which led to intron retention
(Supek et al., 2014; Jung et al., 2015). For example, an intronic
mutation in BRAF induces the expression of a splice variant
that confers resistance to vemurafenib treatment in melanoma
(Salton et al., 2015). These aberrant or cancer-specific isoforms
are generally detected using short- and/or long-read mRNA
sequencing, and are usually validated using mini-gene constructs
carrying the different SNV alleles in low- or high-throughput
assay formats (Gaildrat et al., 2010; Cavelier et al., 2015;
Rosenberg et al., 2015; Li Y. et al., 2017).
FUTURE PERSPECTIVES
Recent studies have identified a handful of somatic SNVs
in regulatory regions that affect TF binding and target gene
expression. However, the number of functional non-coding SNVs
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associated with cancer is expected to be much higher given the
low overlap between those reported in different studies, and given
that non-coding SNVs seem to play an important role in disease
based on the hundreds of functional non-coding SNVs identified
in genome-wide association and genetic studies (Stenson et al.,
2009). Advances in several areas will be needed to increase our
ability to identify these driver mutations. First, larger numbers
of tumor samples with available whole-genome sequence data
are needed to increase statistical power in prediction algorithms.
Second, more refined background models in hotspot analyses that
take into account multiple covariates will help identify functional
regulatory regions in cancer. Finally, improvements in motif
analyses will be needed through the generation of PWMs for
uncharacterized TFs and by identifying in silico parameters that
can accurately predict differential TF binding between alleles.
Another source of underestimation of non-coding driver
SNVs stems from the hotspot analysis itself as it assumes that
driver mutations in a particular regulatory region should be
present in multiple patients. Given the hundreds of thousands
of regulatory elements in the human genome we may be
far from having a sample size sufficiently large to detect
most functional SNVs. An alternative approach would be to
lower the stringency in the statistical pipelines and directly
test thousands of “moderate-confidence” SNVs using MPRAs
to identify functional variants. Ultimately, a combination of
computational and experimental methods along with new
technical innovations will increase our ability to identify and
characterize the mechanisms by which non-coding SNV drive
cancer.
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